News Sentiment

DWTX sentiment intelligence

Dogwood Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.42 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -7.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -7.8% over four weeks
Fair value -82.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 11
Market source 9
Stock Titan 6
simplywall.st 3
TradingView 2
DonanımHaber 2
Investing.com 2
The Standard (HK) 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 18
Deals and strategy 4
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
SEC.gov Direct company coverage

EDGAR Filing Documents for 0001558370-24-013167

This article provides details of an EDGAR Form 8-K filing (SEC Accession No. 0001558370-24-013167) filed by Virios Therapeutics, Inc. The filing date was October 7, 2024, with a period of report ending October 4, 2024. It covers various items, including material definitive agreem

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 13:40
Source
SEC.gov
Finviz Direct company coverage

DWTX - Dogwood Therapeutics Inc Stock Price and Quote

This page provides a detailed stock quote and company information for Dogwood Therapeutics Inc (DWTX), including its current stock price, financial metrics, insider and institutional ownership, and recent performance. It also lists significant news events and announcements relate

Tone
Negative 39/100
Event
Market update
Published
01 Jun 2026 23:39
Source
Finviz
GlobeNewswire Direct company coverage

Dogwood Therapeutics Announces Worldwide Development and

Dogwood Therapeutics has announced a global development and commercialization partnership with PRIDCor Therapeutics for its anti-viral candidates, IMC-1 and IMC-2, with potential payments of up to $100 million. This agreement allows Dogwood to shift its focus to its lead pain and

Tone
Positive 74/100
Event
Deals and strategy
Published
23 Apr 2026 09:00
Source
GlobeNewswire